If approved, ziftomenib could be the first FDA-approved Menin inhibitor for relapsed/refractory acute myeloid leukemia with ...

Panelists discuss the primary access challenges in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) treatment, including financial barriers and health care system limitations, and how ...

Recent advances in cancer research have underscored the critical role of myeloid cells in shaping tumor microenvironments ...

Investigators aim to establish an optimal dose and explore CER-1236's safety and preliminary anti-tumor activity.